首页> 外文会议>International Symposium on Hormonal Carcinogenesis >Constitutively Active Androgen Receptor Variant Detected in a Human Prostate Cancer
【24h】

Constitutively Active Androgen Receptor Variant Detected in a Human Prostate Cancer

机译:在人类前列腺癌中检测到组成型活性雄激素受体变体

获取原文

摘要

Human androgen receptor (AR) mutation is a possible alternative used by prostate adenocarcinoma (PCA) cells to escape androgen dependence. These mutations may broaden the specificity and/or the sensitivity of the AR to other hormones, resulting in the inappropriate receptor activation, and thus, affecting the PCA response to hormonal therapies. We have developed a yeast-based functional assay to detect mutant ARs in PCA by analyzing their transactivation capacities in response to different ligands. We report herein the detection of two different mutant ARs within the same metastatic tumor sample. Concomitantly to the T877A mutant AR, we identified an additional double mutant AR harboring the nonsense mutation Q640Stop, just downstream of the DNA binding domain together with the T877A point mutation. This mutation leads to a C-terminal truncated AR. This study is the first description of mis type of mutation in PCA. We demonstrated that this truncated AR exhibited constitutive transactivation properties. In conclusion, our data suggest that mutation-induced constitutive activation of the AR may be an alternative mechanism used by PCA cells to escape androgen deprivation.
机译:人雄激素受体(AR)突变是前列腺腺癌(PCA)细胞用于逃避雄激素依赖性的可能替代方案。这些突变可以扩大AR对其他激素的特异性和/或敏感性,导致不恰当的受体激活,从而影响对荷尔蒙治疗的PCA响应。我们开发了一种基于酵母的功能试验,通过分析其反膜剂能力响应于不同配体来检测PCA中的突变体AR。我们在本文中报告了在同一转移性肿瘤样品中检测两种不同的突变体ARS。伴随到T877A突变体AR,我们鉴定了一种额外的双突变体AR,其含有非阵容突变Q640Stop,与T877A点突变一起下游。该突变导致C末端截短的AR。本研究是PCA中MIS类型突变的第一个描述。我们证明,该截短的AR表现出本构型转移性质。总之,我们的数据表明,突变诱导的AR的组成型激活可以是PCA细胞使用以逃避雄激素剥夺的替代机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号